Lung Diseases, Interstitial
FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths
FDA partial clinical hold; ifinatamab deruxtecan; I-DXd; IDeate-Lung02; Merck; Daiichi Sankyo; small cell lung cancer; interstitial lung disease; grade 5 ILD; antibody-drug conjugate; clinical trial deaths
aTyr’s Steroid-Sparing Lung Disease Drug Disappoints in Late-Stage Trial
aTyr Pharma; efzofitimod; steroid-sparing; pulmonary sarcoidosis; interstitial lung disease
Advancements in Pulmonary Hypertension and Interstitial Lung Disease: Emerging Therapies and Clinical Trial Designs
Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools
Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer
Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease
FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease
YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso